MYC and Familial prostate cancer: Understanding the link between c-MYC and the ABCC1/LPI pathway would help clarifying whether c-MYC overexpression in prostate cancer is associated with a hyperactive ABCC1/LPI pathway and could potentially provide a criterion to identify patients who might benefit from combined Docetaxel/S3 treatment.